Rhinorin nasal spray doses 50ml

Rinorin

Solution for moisturizing the nasal mucosa Rinorin

RU No. FSZ 2009/04315 dated May 13, 2009

Trade name: Rhinorin

Release form: nasal spray 50 ml

Composition: 1 ml of Rhinorin solution contains 7.72 mg of sodium chloride, 0.42 mg of potassium chloride, 0.16 mg of calcium chloride.

Excipients: benzalkonium chloride - 0.1 mg, sodium hydroxide, hydrochloric acid (to ensure pH and stabilization) and purified water.

Properties

Rhinorine is an isotonic saline solution that helps moisturize and maintain the normal physiological state of the nasal mucosa.

Rhinorin helps remove viruses, bacteria, allergens, aeropollutants from the mucous membrane of the nasal cavity, and reduces the manifestations of the local inflammatory process. It has an antiseptic effect due to the benzalkonium chloride included in the composition.

After using Rinorin, the therapeutic effectiveness of drugs used intranasally increases. Helps thin mucus.

Indications for use:

• prevention of respiratory viral and allergic diseases;
• use in the complex treatment of respiratory viral and allergic diseases, such as rhinitis, sinusitis, adenoiditis, ARVI, allergic rhinitis, especially in dry or cold weather, or when staying in rooms with central heating or air conditioning, in crowded places;
• hygienic care for the nasal mucosa in children and adults - for careful cleansing of viruses, bacteria, allergens and aeropollutants;
• moisturizing and eliminating dryness of the nasal mucosa, including for drivers and passengers of motor vehicles and electric vehicles, as well as during air travel and during climate change;
• prevention of dryness of the nasal mucosa in persons who are near operating electronic and electrical devices for more than 40 minutes;
• as an additional remedy for rhinitis.

Contraindications: Hypersensitivity to any of the components of Rhinorin spray.

Use in childhood, pregnancy and lactation:

Rhinorine is approved for use in childhood. Before use, you should consult a specialist.

Rhinorin is approved for use during pregnancy (1-3 trimester) and lactation.

Possible side effects

Application may be accompanied by short-term itching in the nose and sneezing. Rhinorin spray contains benzalkonium chloride, which can cause an allergic reaction. If you suspect that the use of Rhinorin spray has caused a side effect, you should consult a doctor.

Nasal rinsing technique:

Before first use, spray Rinori spray in the air 2-4 times to achieve a more even spray. To do this, smoothly, without effort, press the horizontal part of the nozzle, positioning the cylinder vertically with the nozzle up, as shown in the figure.

Shallowly, 1 -1.5 cm, insert the tip into the nasal passage, trying to avoid contact of the tip with the nasal mucosa. The bottle must be held vertically and the head must not be tilted. During irrigation, it is necessary to breathe through the nostril into which the injection is made, while closing the other nostril by lightly pressing on it with the index finger of the other hand. Gently press the dispensing tip with two fingers. Apply 1-3 sprays of nasal spray into the nasal passage. Blow your nose if necessary.

Repeat the procedure with the other nasal passage.

Close the dispensing nozzle with the cap.

The duration of use is not limited.

Directions for use: 1-3 sprays 1-3 times in each nasal passage as needed.

A larger amount of solution can be used to rinse the nasal mucosa if there are crusts in the nose. The solution is also used to relieve nasal congestion before using a medicated nasal spray.

Storage conditions: Store at a temperature not exceeding 25 ºС.

Keep out of the reach of children.

Do not refrigerate or freeze.

Packaging: 50 ml plastic bottle with a plastic spray nozzle and a plastic cap, in a cardboard box.

Best before date:

2 years.

Once opened, the bottle can be used until the expiration date.

Do not use after expiration date.

Conditions for dispensing from pharmacies:

Over the counter.

Manufacturer:

Orion Corporation,

Orioninti 1, P/O Box 65, 02101 Espoo, Finland

Consumer complaints should be sent to the Representative in Moscow:

Orion Pharma LLC, 119034. Moscow, Sechenovsky per., 6/3, Tel. (495) 363-50-71, 72.

Delta Medical

Home page of the drug Rhinorin

Solution for moisturizing the nasal mucosa Rinorin

RU No. FSZ 2009/04315 dated May 13, 2009

Trade name: Rhinorin

Release form: nasal spray 50 ml

Composition: 1 ml of Rhinorin solution contains 7.72 mg of sodium chloride, 0.42 mg of potassium chloride, 0.16 mg of calcium chloride.

Excipients: benzalkonium chloride - 0.1 mg, sodium hydroxide, hydrochloric acid (to ensure pH and stabilization) and purified water.

Properties

Rhinorine is an isotonic saline solution that helps moisturize and maintain the normal physiological state of the nasal mucosa.

Rhinorin helps remove viruses, bacteria, allergens, aeropollutants from the mucous membrane of the nasal cavity, and reduces the manifestations of the local inflammatory process. It has an antiseptic effect due to the benzalkonium chloride included in the composition.

After using Rinorin, the therapeutic effectiveness of drugs used intranasally increases. Helps thin mucus.

Indications for use:

• prevention of respiratory viral and allergic diseases;
• use in the complex treatment of respiratory viral and allergic diseases, such as rhinitis, sinusitis, adenoiditis, ARVI, allergic rhinitis, especially in dry or cold weather, or when staying in rooms with central heating or air conditioning, in crowded places;
• hygienic care for the nasal mucosa in children and adults - for careful cleansing of viruses, bacteria, allergens and aeropollutants;
• moisturizing and eliminating dryness of the nasal mucosa, including for drivers and passengers of motor vehicles and electric vehicles, as well as during air travel and during climate change;
• prevention of dryness of the nasal mucosa in persons who are near operating electronic and electrical devices for more than 40 minutes;
• as an additional remedy for rhinitis.

Contraindications: Hypersensitivity to any of the components of Rhinorin spray.

Use in childhood, pregnancy and lactation:

Rhinorine is approved for use in childhood. Before use, you should consult a specialist.

Rhinorin is approved for use during pregnancy (1-3 trimester) and lactation.

Possible side effects

Application may be accompanied by short-term itching in the nose and sneezing. Rhinorin spray contains benzalkonium chloride, which can cause an allergic reaction. If you suspect that the use of Rhinorin spray has caused a side effect, you should consult a doctor.

Nasal rinsing technique:

Before first use, spray Rinori spray in the air 2-4 times to achieve a more even spray. To do this, smoothly, without effort, press the horizontal part of the nozzle, positioning the cylinder vertically with the nozzle up, as shown in the figure.

Shallowly, 1 -1.5 cm, insert the tip into the nasal passage, trying to avoid contact of the tip with the nasal mucosa. The bottle must be held vertically and the head must not be tilted. During irrigation, it is necessary to breathe through the nostril into which the injection is made, while closing the other nostril by lightly pressing on it with the index finger of the other hand. Gently press the dispensing tip with two fingers. Apply 1-3 sprays of nasal spray into the nasal passage. Blow your nose if necessary.

Repeat the procedure with the other nasal passage.

Close the dispensing nozzle with the cap.

The duration of use is not limited.

Directions for use: 1-3 sprays 1-3 times in each nasal passage as needed.

A larger amount of solution can be used to rinse the nasal mucosa if there are crusts in the nose. The solution is also used to relieve nasal congestion before using a medicated nasal spray.

Storage conditions: Store at a temperature not exceeding 25 ºС.

Keep out of the reach of children.

Do not refrigerate or freeze.

Packaging: 50 ml plastic bottle with a plastic spray nozzle and a plastic cap, in a cardboard box.

Best before date:

2 years.

Once opened, the bottle can be used until the expiration date.

Do not use after expiration date.

Conditions for dispensing from pharmacies:

Over the counter.

Manufacturer:

Orion Corporation,

Orioninti 1, P/O Box 65, 02101 Espoo, Finland

Consumer complaints should be sent to the Representative in Moscow:

Orion Pharma LLC, 119034. Moscow, Sechenovsky per., 6/3, Tel. (495) 363-50-71, 72.

The work analyzes the effectiveness of treatment of chronic adenoiditis in children using the complex drug Rhinorin (Orion, Finland) in comparison with traditional methods of treatment, both with and without the use of irrigation therapy. The results obtained show that the use of the drug Rhinorin in the complex treatment of chronic adenoiditis significantly increases its effectiveness, significantly reducing the severity of clinical symptoms and helping to reduce the frequency of disease relapses. At the same time, the use of the modern complex drug Rhinorin, due to its ease of use, is rated by patients significantly higher than traditional drugs and increases compliance.

Effectiveness of Rinorin in treatment of chronic adenoiditis in children

It was analyzed the effectiveness of the treatment of chronic adenoiditis in children with complex preparation Rinorin (Orion, Finland) as compared with conventional treatments, as with or without the use of irrigation treatment. The results show that the use in treatment of chronic adenoiditis, the drug Rinorin greatly increases its effectiveness, significantly reducing the severity of clinical symptoms and helping to reduce the frequency of relapses. In this case, the use of modern complex preparation Rinorin, thanks to convenience of application, patients estimated to be significantly higher compared with conventional therapy and improve compliance.

Chronic adenoiditis is a chronic inflammatory polyetiological disease, which is based on a violation of the physiological immune processes of the pharyngeal tonsil, often occurring against the background of its hyperplasia, manifested by frequent runny nose, difficulty in nasal breathing and contributing to the development of inflammatory pathology of the nose, paranasal sinuses, ear and lower respiratory tract, deformation facial skeleton, etc. [1, 2]. Hypertrophy of the pharyngeal tonsil and chronic adenoiditis are among the most common diseases of childhood. According to preventive examination data, this pathology is detected in 35.3% of children under the age of 7 years [3]. Chronic adenoiditis accompanies chronic and recurrent diseases of the bronchopulmonary system in 50% of children with this pathology, and sinusitis is also detected in 40% of children [4]. In addition, in childhood, the development of chronic adenoiditis can be caused by acid-dependent pathology of the gastrointestinal tract, which is widespread in developed countries: inflammation of the pharyngeal tonsil accompanies GERD in 70% of children [5, 6].

Existing treatment methods are divided into surgical and conservative. When choosing a treatment method, it is necessary to take into account that the pharyngeal tonsil is a secondary peripheral organ of the immune system and has a unique structural organization that allows it not only to function as an immune barrier, but also to carry out lymphopoiesis, providing the mucous membrane of the upper and lower respiratory tract with immune-competent cells. The active participation of the pharyngeal tonsil in the ontogenetic development of immunity determines a careful attitude towards the organ. In this regard, in case of chronic adenoiditis, even accompanied by persistent impairment of nasal breathing, it is advisable to carry out complex conservative therapy, including irrigation methods of treatment, antiseptic drugs, antibacterial drugs, mucolytics, topical glucocorticoids, immunomodulators, herbal remedies, complex homeopathic remedies, physiotherapy, etc. . [7].

The feasibility of using irrigation therapy is determined not only by the need to eliminate antigens from the mucous membrane. In recent years, numerous studies have shown that bacterial associations of such microorganisms that are significant in the development of chronic adenoiditis, such as S.aureus, Str.pneumoniae and Ps.aeruginosa, form so-called biofilms, which increase the resistance of bacteria to antibacterial drugs by an order of magnitude, contributing to the persistence of inflammation. Biofilms are found in 85% of children suffering from chronic inflammation of the pharyngeal tonsil [8]. Biofilms cover an average of 93.5% of the surface of adenoid vegetations in patients suffering from chronic adenoiditis in combination with recurrent acute otitis media, which is statistically significantly higher (p <0.0001) compared to children suffering from obstructive sleep apnea syndrome caused by hypertrophy adenoid vegetations without recurrent otitis, in which biofilms cover on average only 1% of the surface of the pharyngeal tonsil [9]. It should also be taken into account that in pediatric practice today the effectiveness of irrigation therapy only with isotonic saline solutions has been proven [1].

When prescribing complex therapy, especially in pediatrics, it is necessary to remember that treatment compliance decreases with an increase in the number of recommended drugs. Therefore, it is advisable, if possible, to prescribe drugs that have a complex effect. One of these products intended for irrigation therapy is the drug Rhinorin (Orion, Finland). In addition to sodium, potassium and calcium chloride salts, which create an isotonic solution, the drug Rinorin contains benzalkonium chloride, which, by disrupting the integrity of the cell membranes of microorganisms, has a wide spectrum of antimicrobial and antifungal activity, and also slows down the proliferation of viruses. Along with its inherent antibacterial activity, benzalkonium chloride has an adverse effect on the cellular respiration of bacteria, which is probably due to the uncoupling of oxidative phosphorylation. This ability further allows for the destruction and elimination of biological films, which pose a particular problem in patients with chronic bacterial diseases.

Goal of the work:

To study the effectiveness of treatment of chronic adenoiditis in children using the complex drug Rhinorin.

Patients and methods:

The criteria for inclusion in the study were clinical and anamnestic data of chronic adenoiditis: the presence of characteristic complaints (nasal congestion, nasal discharge, a feeling of mucus running down the back of the throat, night and morning cough); adenoid vegetations of the I-II degree, detected by endoscopy; smoothness and hyperemia of the mucous membrane of the pharyngeal tonsil; the presence of mucopurulent exudate on the adenoids; drainage of mucopurulent discharge down the back wall of the pharynx or its “hanging” due to the soft palate; the duration of the disease is at least 1 month. To examine the nasal cavity and nasopharynx, we used rigid K.Storz rhinoscopes with a viewing angle of 00 and 300 and pediatric fibrorhinolaryngoscopes Pentax FNL-7RP3, with a diameter of 2.5 mm (the examination was carried out at the initial visit and at the final visit).

Exclusion criteria were: grade III adenoid vegetations; obstructive sleep apnea syndrome; the need for systemic antibacterial therapy at initial treatment or during the study; self-cessation of treatment or failure to appear for a follow-up examination.

The study included 90 children (44 girls and 46 boys) aged from 2.5 to 14 years (mean age 5.6 ± 2.98 years), randomized into 3 groups. Group 1 included 30 children (average age 6.0 ± 3.22 years) who received irrigation therapy with Rhinorin, 3 doses (injections) into each half of the nose 3 times a day for at least 1 month. Group 2 included 30 children (average age 5.8 ± 3.0 years), who were prescribed irrigation therapy with saline solution 3-5 ml in each half of the nose 3 times a day for at least 1 month; Additionally, patients in this group were prescribed endonasal administration of a 2% solution of silver proteinate, 2-3 drops after rinsing the nose during the first 2 weeks. Patients of group 3 (average age 5.9 ± 2.68 years) were prescribed endonasal administration of a 2% solution of silver proteinate, 2-3 drops 3 times a day for 2 weeks. The groups were statistically comparable by age and gender (p>0.05). In addition, all patients were prescribed for 2 weeks, in an age-specific dosage, a combination herbal preparation Sinupret (Bionorica, Germany), which has secretolytic, secretomotor, anti-inflammatory and immunostimulating effects.

The criteria for the effectiveness of treatment were: subjective assessment (degree of nasal congestion, presence, nature and amount of discharge), assessed by the patient or his parents using a visual analogue scale (VAS), where 0 points is the absence of a symptom, and 5 points is its maximum severity; an objective assessment was made on the basis of nasopharyngoscopy and endoscopy of the nose and nasopharynx; the presence or absence of relapse of adenoiditis. Additionally, at the second and final visit, the patients’ parents assessed treatment compliance using a 5-point VAS, where a score of “5 points” corresponded to complete satisfaction with the prescribed therapy.

A follow-up examination was carried out 14 days and 3 months after the start of treatment.

Results:

At the time of inclusion in the study, the severity of complaints and clinical symptoms in the groups were statistically comparable (p>0.05) (Table 1).

Table 1.

Dynamics of clinical trial data

Notes:

* - statistically significant difference (p < 0.05) compared with the severity of the symptom in the group at treatment;

# - statistically significant difference (p < 0.05) between groups 2 and 3;

§ — statistically significant difference (p < 0.05) between 1st and 2nd; 1st and 3rd groups;

^—statistically significant difference (p < 0.05) between groups 1 and 3.

In particular, parents of all children in group 1 complained of nasal congestion of varying severity (the severity of the symptom according to the VAS score was 3.2 ± 1.27 points); 26 patients (86.7%) - in group 2 (symptom severity 2.6 ± 1.54 points); and 27 patients (90%) - in group 3 (symptom severity 3.0 ± 1.48 points). Mucous and mucopurulent nasal discharge was present in 19 (63.3%) patients in group 1; 25 (83.3%) - in group 2; and in 22 (73.3%) - in the 3rd group. Parents of patients assessed the severity of symptoms according to VAS accordingly: 2.1 ± 1.8 points; at 2.8 ± 1.64 points and at 2.1 ± 1.68 points. Night and morning cough was observed in 17 (56.7%) children in group 1; 15 (50%) - in group 2; and in 13 (43.3%) - in the 3rd group. During nasopharyngeal endoscopy, grade I adenoid vegetations were diagnosed in 6 (20%) patients of group 1; in 10 (33.3%) patients each - in groups 2 and 3. The remaining patients were diagnosed with grade II hypertrophy of the pharyngeal tonsil.

By the 14th day, 5 patients from groups 1 and 3 and 7 from group 2 dropped out of the study (due to failure to attend a follow-up examination or due to the need for systemic antibiotic therapy). In all groups, there was a statistically significant (p <0.05) positive dynamics compared to the initial examination. Although complaints of nasal congestion persisted in 18 out of 25 (72%) children in group 1, in 14 out of 23 (60.9%) in group 2, and in 19 out of 25 (76%) in group 3, the severity of the symptom according to VAS significantly decreased and averaged 1.2 ± 1.02, 1.1 ± 1.04 and 1.6 ± 1.11 points, respectively (Diagram 1).

Diagram 1.

The degree of difficulty in nasal breathing (Me), according to the visual analogue scale

At the same time, a statistically significant difference (p = 0.038) was noted in the severity of the symptom between patients of the 2nd and 3rd groups. Mucous and mucopurulent nasal discharge persisted in 16 (64%) children in group 1; 16 (69.6%) - in group 2; and 17 (68%) - in group 3; Parents assessed their severity according to VAS on average accordingly: 1.04 ±0.99; 1.13 ± 0.95; and 1.46 ± 1.15 points (the difference between the groups is statistically insignificant, p>0.05) (Diagram 2).

Diagram 2.

The severity of rhinorrhea (Me), according to the visual analogue scale

Night and morning cough persisted in 7 (28%) patients in group 1; 7 (30.4%) - in group 2; and in 9 (36%) - in group 3 (the difference between the groups is statistically insignificant, p>0.05). Despite the generally comparable treatment results, the parents' assessment of treatment compliance on the 14th day of treatment in patients in group 1 (average score 4 ± 0.96 points) was statistically significantly higher compared to the indicator in group 2 (average score 3.5 ± 0.97 points) and 3rd (average score 3.3 ± 1.07 points) groups (p = 0.038 and p = 0.015, respectively); Moreover, this indicator between patients of the 2nd and 3rd groups was statistically comparable (p = 0.32) (Diagram 3).

Diagram 3.

Therapy assessment (Me), according to the visual analogue scale

The study was completed by presenting for a follow-up examination 3 months after the start of treatment, 20 children in group 1 and 17 patients each in groups 2 and 3. In all groups of patients, when comparing the clinical results obtained during the previous examination with follow-up data, the effect of treatment remained. In particular, complaints of nasal congestion remained in 10 (50%) patients of group 1; 10 (58.8%) - in group 2; and in 11 (64.7%) - in group 3, however, the severity of the symptom according to VAS was insignificant and averaged respectively: 0.75 ± 0.89; 1.0 ± 1.03; and 1.2 ± 1.11 points. Mucous discharge from the nose remained in 10 (50%) children in group 1 (VAS score, on average, 0.7 ± 0.84 points); in 11 (64.7%) - in group 2 (1.0 ± 0.91 points); and in 11 (64.7%) - in group 3 (1.2 ± 1.09 points). Night and morning cough persisted in 6 (30%) patients of group 1; 5 (29.4%) - in group 2; and in 7 (41.2%) - in group 3 (the difference in all indicators between the groups is statistically insignificant, p>0.05). However, only in patients of the 1st and 2nd groups, endoscopy of the nasopharynx revealed a statistically significant decrease in the size of the pharyngeal tonsil in the group as a whole compared to the initial level: adenoid vegetations of the 1st degree were diagnosed in 12 (60%) children of the 1st group ( p=0.005); in 11 (64.7%) - in group 2 (p = 0.46); and in 12 (70.6%) - in group 3 (p = 0.087). As with the previous examination, parents' assessment of compliance with therapy was statistically significantly higher in patients of group 1 (average score 4.1 ± 0.79) compared with a score of 3.5 ± 1.09 points in group 2 and 3 .5 ± 0.91 points - in group 3 (p = 0.03 and p = 0.01, respectively); the assessment of the convenience and effectiveness of therapy by parents of patients in groups 2 and 3 did not differ statistically (p = 0.43).

During the follow-up examination, the frequency of episodes of acute and exacerbation of chronic adenoiditis was additionally assessed. The best result was observed in patients of group 1: only 6 (30%) children had 1 to 2 episodes of the disease during observation (group average - 0.35 ± 0.57), compared with children in group 2. group 1 (from 1 to 3 exacerbations in 7 (41.2%), group average - 0.7 ± 0.95) and in group 3 (from 1 to 3 exacerbations in 9 (52.9%) , on average for the group - 0.8 ± 0.92, which is statistically significantly more common compared to group 1 (p = 0.043).

Conclusion:

The study showed that the use of the drug Rhinorin (Orion, Finland) in the complex treatment of chronic adenoiditis significantly increases its effectiveness, significantly reducing the severity of clinical symptoms, and helps reduce the frequency of relapses of the disease. At the same time, the use of modern complex drugs, such as Rhinorin, due to their ease of use, is rated significantly higher by patients compared to traditional drugs and increases compliance.

Yu.L. Soldatsky, E.K. Onufrieva, S.F. Gasparyan, A.M. Steklov, N.V. Shchepin, S.N. Popova

First Moscow State Medical University named after. THEM. Sechenov

Children's City Clinical Hospital of St. Vladimir, Moscow

Soldatsky Yuri Lvovich - Doctor of Medical Sciences, Professor, scientific group at the Department of Ear, Nose and Throat Diseases

Literature:

1. Karpova E.P., Tulupov D.A. Chronic adenoiditis in children. — A manual for doctors. - M., 2009. - 53 p.

2. Rymsha M.A., Chaukina V.A. Chronic inflammatory diseases of the pharynx in children / Diseases of the ear, nose and throat in childhood: national guidelines / ed. M.R. Bogomilsky, V.R. Chistyakova. - M.: GEOTAR-Media, 2008. - P. 336-356.

3. Borzov E.V. Prevalence of ENT pathology in children // News of otorhinolaryngology and logopathology. - 2001. - No. 1 (29). — P. 3-5.

4. Feigina V.M. ENT pathology in some chronic nonspecific lung diseases in children: abstract. dis. ... Ph.D. - M., 1999. - 25 p.

5. Karpova E.P., Tulupov D.A., Zavictorina T.G. Microbiocenosis of the nasopharynx in children with chronic adenoiditis associated with gastroesophageal reflux disease (GERD) / VII scientific and practical conference “Pharmacological and physical methods of treatment in otorhinolaryngology”: Materials. - M., 2009. - P. 18.

6. Harris PK, Hussey DJ, Watson DI et al. Reflux changes in adenoidal heperplasia: a controlled prospective study to investigate its aetiology // Clin Otolaryngol. - 2009. - Vol. 34. - No. 3. - R. 120-126.

7. Borzov E.V. Adenoids / Pediatric otorhinolaryngology: A guide for doctors / ed. M.R. Bogomilsky, V.R. Chistyakova. - In two volumes. - T. 1. - M.: Medicine, 2005. - P. 296-307.

8. Al-Mazrou KA, Al-Khattaf AS Adherent biofilms in adenotonsillar diseases in children // Arch Otolaryngol Head Neck Surg. - 2008. - Vol. 134. - No. 1. - R. 20-23.

9. Zuliani G., Carlisle M., Duberstein A. et al. Biofilm density in the pediatric nasopharynx: recurrent acute otitis media versus obstructive sleep apnea // Ann Otol Rhinol Laryngol. - 2009. - Vol. 118. - No. 7. - R. 519-524.